Study Comparing Cyclosporin Dose Reduction With Cyclosporin Elimination in Kidney Transplant Recipients Taking Sirolimus
Kidney Disease
About this trial
This is an interventional prevention trial for Kidney Disease focused on measuring Kidney Disease
Eligibility Criteria
Inclusion Criteria: Age: = to ≥ 18 years. End-stage renal disease, with patients scheduled to receive a primary or secondary renal allograft from a cadaveric donor, from a living-unrelated donor, or from a living-related donor. Patients with second and subsequent transplants must have maintained their primary graft for at least 6 months after transplantation (with the exception of graft failure due to technical reasons). Exclusion Criteria: Evidence of active systemic or localised major infection prior to initial Rapamune® administration. Evidence of infiltrate, cavitation, or consolidation on chest x-ray obtained during screening. Use of any investigational drug or treatment up to 4 weeks prior to enrolling in the study and during the 12-month treatment phase. Exception: the use of erythropoiesis stimulating products. In these cases, erythrocyte-stimulating products must be discontinued prior to administration of Rapamune®.